Monoamine oxidase inhibitor

Monoamine oxidase inhibitor
Drug class
Ribbon diagram of human monoamine oxidase B, from PDB: 1GOS
Class identifiers
SynonymsMAOI, RIMA
UseTreatment of major depressive disorder, atypical depression, Parkinson's disease, and several other disorders
ATC codeN06AF
Mechanism of actionEnzyme inhibitor
Biological targetMonoamine oxidase enzymes:
MAO-A and/or MAO-B
External links
MeSHD008996
Legal status
In Wikidata

Monoamine oxidase inhibitors (MAOIs) are a class of drugs that inhibit the activity of one or both monoamine oxidase enzymes: monoamine oxidase A (MAO-A) and monoamine oxidase B (MAO-B). They are effective antidepressants, especially for treatment-resistant depression[1] and atypical depression.[2] They are also used to treat panic disorder, social anxiety disorder, Parkinson's disease, and several other disorders.

Reversible inhibitors of monoamine oxidase A (RIMAs) are a subclass of MAOIs that selectively and reversibly inhibit the MAO-A enzyme. RIMAs are used clinically in the treatment of depression and dysthymia. Due to their reversibility, they are safer in single-drug overdose than the older, irreversible MAOIs,[3] and weaker in increasing the monoamines important in depressive disorder.[4] RIMAs have not gained widespread market share in the United States.

  1. ^ Eynde, Vincent Van den; Abdelmoemin, Wegdan R.; Abraham, Magid M.; Amsterdam, Jay D.; Anderson, Ian M.; Andrade, Chittaranjan; Baker, Glen B.; Beekman, Aartjan T. F.; Berk, Michael; Birkenhäger, Tom K.; Blackwell, Barry B.; Blier, Pierre; Blom, Marc B. J.; Bodkin, Alexander J.; Cattaneo, Carlo I. (August 2023). "The prescriber's guide to classic MAO inhibitors (phenelzine, tranylcypromine, isocarboxazid) for treatment-resistant depression". CNS Spectrums. 28 (4): 427–440. doi:10.1017/S1092852922000906. hdl:2292/61637. ISSN 1092-8529.
  2. ^ Cristancho, Mario A. (20 November 2012). "Atypical Depression in the 21st Century: Diagnostic and Treatment Issues". Psychiatric Times. Archived from the original on 2 December 2013. Retrieved 23 November 2013.
  3. ^ Isbister GK, et al. (2003). "Moclobemide poisoning: toxicokinetics and occurrence of serotonin toxicity". British Journal of Clinical Pharmacology. 56 (4): 441–450. doi:10.1046/j.1365-2125.2003.01895.x. PMC 1884375. PMID 12968990.
  4. ^ "Neuroscience Education Institute > Activities > 2012CurbConsultPosted". www.neiglobal.com.